NASDAQ:AXLA - Axcella Health Stock Price, Forecast & News

Axcella Health trades on the NASDAQ under the ticker symbol "AXLA."

Axcella Health Inc (NASDAQ:AXLA) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.75) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by $0.04. View Axcella Health's Earnings History.

Axcella Health is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Axcella Health.

4 brokerages have issued 12 month price targets for Axcella Health's stock. Their forecasts range from $20.00 to $25.00. On average, they anticipate Axcella Health's stock price to reach $22.00 in the next twelve months. This suggests a possible upside of 378.3% from the stock's current price. View Analyst Price Targets for Axcella Health.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axcella Health in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Axcella Health.

Press coverage about AXLA stock has trended somewhat positive this week, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Axcella Health earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Axcella Health.

Axcella Health saw a drop in short interest in January. As of January 31st, there was short interest totalling 108,000 shares, a drop of 12.1% from the January 15th total of 122,800 shares. Based on an average daily volume of 66,300 shares, the short-interest ratio is presently 1.6 days. Currently, 1.3% of the shares of the company are short sold. View Axcella Health's Current Options Chain.

Some companies that are related to Axcella Health include Scholar Rock (SRRK), Autolus Therapeutics (AUTL), PDL BioPharma (PDLI), Precision BioSciences (DTIL), Adaptimmune Therapeutics (ADAP), Cabaletta Bio (CABA), BioCryst Pharmaceuticals (BCRX), Gritstone Oncology (GRTS), Harpoon Therapeutics (HARP), Tcr2 Therapeutics (TCRR), Cellular Biomedicine Group (CBMG), Eiger Biopharmaceuticals (EIGR), Sutro Biopharma (STRO), Novavax (NVAX) and ADMA Biologics (ADMA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Axcella Health investors own include Triton International (TRTN), Main Street Capital (MAIN), Agile Therapeutics (AGRX), vTv Therapeutics (VTVT), Vaxart (VXRT), Armata Pharmaceuticals (ARMP), Aduro BioTech (ADRO), Amarin (AMRN), Aytu Bioscience (AYTU) and Exelixis (EXEL).

(AXLA) raised $76 million in an IPO on Thursday, May 9th 2019. The company issued 3,600,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and SVB Leerink served as the underwriters for the IPO.

Axcella Health's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (13.90%), State Street Corp (0.25%), Geode Capital Management LLC (0.17%), Bank of New York Mellon Corp (0.09%), UBS Group AG (0.08%) and Charles Schwab Investment Management Inc. (0.07%). Company insiders that own Axcella Health stock include Catherine A Sohn, D Clay Bretches, David R Epstein, Laurent Chardonnet and Ventures Fund Iv LP Flagship. View Institutional Ownership Trends for Axcella Health.

AXLA stock was sold by a variety of institutional investors in the last quarter, including FMR LLC. View Insider Buying and Selling for Axcella Health.

AXLA stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Geode Capital Management LLC, Bank of New York Mellon Corp, UBS Group AG, Charles Schwab Investment Management Inc., Jacobs Levy Equity Management Inc. and Barclays PLC. Company insiders that have bought Axcella Health stock in the last two years include Catherine A Sohn, D Clay Bretches, David R Epstein, Laurent Chardonnet and Ventures Fund Iv LP Flagship. View Insider Buying and Selling for Axcella Health.

Shares of AXLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AXLA stock can currently be purchased for approximately $4.60.

Axcella Health has a market capitalization of $106.32 million. View Additional Information About Axcella Health.

The official website for Axcella Health is http://www.axcellahealth.com/.

Axcella Health's mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-320-2200.